Sun, Apr 20, 2014, 12:49 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Optimer Pharmaceuticals, Inc. (OPTR) Message Board

  • maguro2000 maguro2000 Dec 12, 2012 9:13 PM Flag

    Termination of Senior VP of Operations

    Does anyone know what that was about? Not a good sign.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Background*
      Mr. Gregory Papaz served as Senior Vice President of U.S. Commercial Operations at Optimer Pharmaceuticals, Inc., since December 2010 until December 11, 2012. Mr. Papaz lead the preparations for the planned commercialization of fidaxomicin. He has more than thirty years of experience in the healthcare and pharmaceutical industry managing pharmaceutical sales teams. Prior to joining Optimer, Mr. Papaz held the position of Rheumatology Sales Director, Commercial Marketing ... at Genentech where he was responsible for planning and launching Actemra(R), a drug for rheumatoid arthritis. In this role, Mr. Papaz staffed a 130-person sales team which sold directly into hospitals, with direct contact to hospital pharmacies physician leaders and hospital management. Prior to Genentech, he worked for Roche Pharma as the Anemia National Sales Director. Prior to Roche Pharma, Mr. Papaz served as the Vice President, Cardiovascular Hospital Sales at Sanofi-Aventis. While in this position, he merged and restructured the Sanofi hospital team with the Aventis Advanced Therapeutics team. Mr. Papaz began his career as a sales representative for Marion Laboratories and was quickly promoted into larger sales leadership roles over the next thirty years, including Vice President, Bone/CNS Sales, followed by Vice President, Oncology Sales at Aventis Pharmaceuticals prior to his position at Sanofi-Aventis. Mr. Papaz received his MBA from the Johnson School of Business at Cornell University. He holds a #$%$ in Hospital and Healthcare Administration from Providence College.

 
OPTR
12.780.00(0.00%)Oct 23 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.